Correction: Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week,Randomized,Non-Inferiority,Open-Label,Phase IIIb Study
Free accessCorrectionFirst published online July, 2017
Correction: Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week,Randomized,Non-Inferiority,Open-Label,Phase IIIb Study
TrottierB., LakeJ.E., LogueK.Dolutegravir/abacavir/ lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.Antivir Ther2017; 22: 295–305.
